Metraipolis › archive › dc_7828b2b0b3a5
Efficacy and safety of CTLA-4, PD-1 and LAG-3 immune checkpoint inhibitors as monotherapy and combination therapy in advanced melanoma: A systematic review… — Europe PMC PMID:41834910
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41834910
- DOI
- 10.17179/excli2025-9096
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T10:22:17.208Z
- SHA-256 of the archived text
cfb9d30586af6dfa94f917d62bb8d8a3bfebe6ce23057800a4693c7d7cf38b01- Stable URL of this page
https://metraipolis.com/documento/dc_7828b2b0b3a5
How to cite
Efficacy and safety of CTLA-4, PD-1 and LAG-3 immune checkpoint inhibitors as monotherapy and combination therapy in advanced melanoma: A systematic review… — Europe PMC PMID:41834910 — Europe PMC (en), https://europepmc.org/article/MED/41834910 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7828b2b0b3a5 (Metraipolis archive dc_7828b2b0b3a5, sha256 cfb9d30586af6dfa94f917d62bb8d8a3bfebe6ce23057800a4693c7d7cf38b01)
BibTeX
@misc{dc7828b2b0b3a5,
title = {Efficacy and safety of CTLA-4, PD-1 and LAG-3 immune checkpoint inhibitors as monotherapy and combination therapy in advanced melanoma: A systematic review… — Europe PMC PMID:41834910},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41834910},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7828b2b0b3a5; sha256 cfb9d30586af6dfa94f917d62bb8d8a3bfebe6ce23057800a4693c7d7cf38b01},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41834910. Agents can read the archived copy with the MCP tool read_document.